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The purposeful induction of the lytic form of Epstein-Barr virus (EBV) infection combined with ganciclovir
(GCV) treatment has been advocated as a novel strategy for EBV-positive B-cell lymphoma. We demonstrated
that rituximab had a synergistic effect with dexamethasone on induction of the lytic EBV infection in CD20-
positive lymphoma cells. Addition of GCV to the dexamethasone/rituximab-treated cells was more effective
than dexamethasone/rituximab alone in killing EBV-positive lymphoma cells in vitro and in lymphoma-bearing
nude mice but not in EBV-negative cells. These data suggest that induction of the lytic EBV infection with
dexamethasone/rituximab in combination with GCV could be a potential virally targeted therapy for EBV-
associated B-cell lymphoma.
Epstein-Barr virus (EBV) is an oncogenic herpesvirus asso-
ciated with a number of human malignancies, including Bur-
kitt’s lymphoma, Hodgkin’s lymphoma, and posttransplanta-
tion lymphoproliferative diseases (17). The presence of the
EBV genome in virtually all of the malignant cells suggests that
novel therapies to specifically kill EBV-infected cells could be
employed to treat these malignancies. Since the majority of
EBV-infected tumor cells carry the EBV genome in a latent
form, antiviral therapy has not been proven useful for treat-
ment of the diseases. One approach would be to induce EBV
lytic infection in tumor cells (10), which may make the cells
susceptible to antiviral drugs, such as ganciclovir (GCV) (15,
24). GCV, itself a cytotoxic prodrug, is converted into a more
active cytotoxic form by the EBV lytic proteins (15, 24). The
switch from latent to lytic infection is mediated by the tran-
scriptional effects of the immediate-early protein encoded by
the EBV BZLF1 gene, which is not expressed during latency
(12). The immediate-early protein can induce the full compo-
nent of early viral lytic genes, such as the BMRF1 gene (12). In
the search for effective treatments to induce the lytic EBV
infection, we found that rituximab, a chimeric anti-CD20
monoclonal antibody, has a synergistic effect with a glucocor-
ticoid, dexamethasone, on induction of lytic EBV infection in
latently EBV-infected B-lymphoma cells. Furthermore, addi-
tion of GCV to the dexamethasone/rituximab-treated cells led
to enhanced cytotoxicity in EBV-positive cells but not in EBV-
negative cells.
In this study, we used the CD20-positive lymphoma Akata
cells. Akata cells carry the EBV genome, but only 1 to 2% of
EBV-positive cells express lytic antigens (23). An EBV-nega-
tive cell clone was isolated from the parental Akata cells by the
limiting-dilution method as previously reported (22). Thus, the
isogenic EBV-positive and EBV-negative Akata cells were
considered to be suitable for our study. Cells were incubated in
RPMI 1640 medium supplemented with 10% fetal calf serum
at 37°C in a humidified atmosphere of 5% CO2 in air and
maintained in log growth phase. Cells were used for experi-
ments only when viability exceeded 95%. We first evaluated
the effects of dexamethasone on induction of the EBV lytic
form. Dexamethasone was purchased from Sigma (St. Louis,
MO). Cells were treated with various concentrations of dexa-
methasone (1 to 100 nM), and 3 days later, viral immunoflu-
orescence was performed to quantitate the number of cells
expressing a viral lytic cycle antigen, early antigen (EA). For
indirect immunofluorescence, cells were washed with phos-
phate-buffered saline (PBS), spotted onto glass slides, and
fixed in acetone. The cells were reacted with a mixture of
monoclonal antibodies (MAbs), R3/C844, against the EBV
EA-diffuse component (EA-D) and the EA-restricted compo-
nent (EA-R) (9). After being washed in PBS, the slides were
incubated with fluorescein isothiocyanate-conjugated anti-
mouse immunoglobulin G (IgG) (Dako, Glostrup, Denmark).
The slides were examined by fluorescence microscopy. At least
1,000 cells were counted for each determination. Dexametha-
sone-treated cells had 3 to 15% of cells expressing the lytic
proteins (Fig. 1A). We then evaluated the effects of rituximab
on induction of lytic EBV infection. Rituximab was provided
by Zenyaku Kogyo Co. (Tokyo, Japan). Rituximab alone, up to
the concentration of 100 g/ml, did not significantly induce
lytic infection. However, combination of dexamathasone with
rituximab resulted in synergistic induction: immunofluores-
cence analysis showed that addition of rituximab (100 g/ml)
enhanced the number of cells expressing the lytic proteins
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approximately four to five times in comparison with dexameth-
asone (10 nM) treatment alone (Fig. 1A). For fluorescence-
activated cell sorting (FACS) analysis, cells were fixed in 4%
paraformaldehyde, washed in staining buffer (PBS with 1%
bovine serum albumin and 0.03% saponin), and incubated with
the mouse MAb R3 (Chemicon, Temecula, CA), which recog-
nizes polypeptides of EA-D (BMRF1 product) (16). Isotype-
matched control antibody was mouse IgG1 (Dako). Fluores-
cein isothiocyanate-conjugated goat anti-mouse IgG was used
as a secondary antibody. Cells were analyzed by Becton Dick-
inson FACScan with CELLQUEST analysis software (San
Jose, CA). FACS analysis also demonstrated that simultaneous
treatment with rituximab and dexamethasone led to enhanced
induction of EA-D (BMRF1 product), approximately four
times compared with dexamethasone treatment alone (Fig.
1B). These results were confirmed by immunoblot analysis
(Fig. 1C). Immunoblot analysis was performed as previously
described (1), and reactive proteins were detected with the
enhanced chemiluminescence system (Amersham, Arlington
Heights, IL). The AZ-69 MAb (Argene, Varilhes, France)
reacts with a polypeptide of ZEBRA (BZLF1 product) (13).
The MAb to -actin (AC-74; Sigma), as an internal control
antibody, was used in parallel to confirm that equal amounts of
protein were loaded in lanes of the gels. Quantitation of signal
intensities of the immunoblots was performed by densitometric
scanning using Light-Capture AE-6962 (Atto, Tokyo, Japan).
Values were normalized to -actin signal intensities of the
same lanes. Addition of rituximab to the dexamethasone-
treated cells resulted in enhanced induction of EA-D (BMRF1
product) and ZEBRA (BZLF1 product), approximately five
and eight times, respectively.
We next examined whether GCV is effective in killing the
EBV-positive and EBV-negative cells treated with dexameth-
asone and rituximab. GCV was supplied from Tanabe Phar-
maceutical Co. (Osaka, Japan). We isolated EBV-negative
cells from the parental Akata cells. The absence of the EBV
genome in the isolated clone was confirmed by PCR (Fig. 2A).
FACS analysis showed that the CD20 antigen was uniformly
expressed in the EBV-positive and EBV-negative cells (Fig.
2B). These cells at an initial concentration of 105 cells/ml were
incubated with no drug or dexamethasone (1 nM or 10 nM)/
rituximab (100 g/ml) in the presence or absence of GCV (20
M). The number of viable cells remaining after the 5-day
incubation was determined by trypan blue exclusion. GCV
alone at a concentration of 20 M did not influence cell
growth. Addition of GCV led to enhanced cell killing in EBV-
positive cells treated with dexamethasone/rituximab (Fig. 2C):
the number of cells surviving the combination treatment with
GCV and dexamethasone/rituximab was reduced significantly
in the EBV-positive cells but not in the EBV-negative cells. In
these experiments, expression of the lytic EBV protein
(BMRF1 product) in the EBV-positive cells treated with dexa-
methasone/rituximab was confirmed by immunoblot analysis
(Fig. 2D). It may be worth noting that treatment of the cells
FIG. 1. Enhanced induction of lytic EBV infection by dexametha-
sone (DEX) and rituximab. (A) Cells were treated with no drug,
rituximab (100 g/ml), DEX at various concentrations, or DEX plus
rituximab for 3 days and examined for EBV lytic EA antigens by
immunofluorescence analysis. Results from four independent experi-
ments are shown. Standard deviation bars are shown with vertical lines.
(B) Induction of EA-D (BMRF1 product) was assayed by FACS anal-
ysis. The percentage of EA-positive cells is shown for each experiment.
Curves defined by dotted lines represent the background fluorescence
obtained on cells stained with the control antibody. (C) Immunoblot
analyses to detect the BZLF1 and BMRF1 products. Lane 1, no treat-
ment; lane 2, DEX (10 nM); lane 3, rituximab (100 g/ml); and lane 4,
DEX/rituximab. The indicated values were normalized to -actin sig-
nal intensities and represent the ratio when signal intensity from the
cells treated with DEX alone was set at 1.0.
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FIG. 2. Dexamethasone (DEX) and rituximab confer GCV susceptibility to EBV-positive cells in vitro and in vivo. (A) The absence of the EBV
genome in the isolated clone (lane 2) from parental EBV-positive Akata cells (lane 1) was confirmed by PCR. The primers were derived from the
sequences corresponding to the EBV BamHI-W region, generating a 129-bp fragment. X174/HincII-cut DNA size markers are also shown.
(B) FACS analysis showed that both EBV-positive and EBV-negative cells uniformly expressed the CD20 antigen. The percentages of CD20-
positive cells are shown. (C) EBV-positive versus EBV-negative cells were treated with no drug or DEX (1 nM or 10 nM) plus rituximab (100
g/ml) in the presence or absence of GCV (20 M) for 5 days. The percentage of viable cells in comparison with untreated control cells (set at
100% viability) is shown. Error bars indicate standard deviations from three independent experiments. (D) Immunoblot analysis confirmed the
expression of the lytic EBV protein (BMRF1 product) in EBV-positive Akata cells treated with DEX (1 nM) plus rituximab (100 g/ml) in the
absence (lane 1) or presence (lane 2) of GCV (20 M) for 5 days. (E) DEX and rituximab induced lytic EBV infection in tumor cells of nude mice.
EBV-positive Akata cells were transplanted into nude mice, and when tumors were formed, the mice were treated with no drug or DEX/rituximab.
Three days later, the tumor extracts were examined for induction of the lytic EBV protein (BZLF1 product) by immunoblot analysis. Lane 1, no
treatment; lane 2, DEX/rituximab. (F) GCV enhanced the cytotoxic effects of DEX/rituximab in nude mice. Nude mice with EBV-positive tumors
(total of 10 tumors in each group from five independent experiments) were given no drug, GCV only, DEX/rituximab, or DEX/rituximab plus
GCV. The relative tumor volume (set at 1.0 on day 0) in each treatment group at various time points after initiation of treatment (day 7, 12, 17,
or 22) is shown. Error bars indicate standard deviations.
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with dexamethasone/rituximab itself showed relative cytotox-
icity (Fig. 2C). The finding is consistent with a previous report
in which Rose et al. (18) demonstrated synergistic cytotoxicity
against CD20-positive B-lymphoma cells in vitro by dexameth-
asone and rituximab.
We examined whether dexamethasone/rituximab treatment
can induce lytic EBV infection in vivo. Female BALB/c nude
mice, 4 to 5 weeks of age, were inoculated with 5  107 cells in
the flanks via subcutaneous injection. Treatment was started 10
to 20 days after transplantation, when tumors reached the size
of 150 to 200 mm3. Mice were treated with one of the follow-
ing: no treatment, dexamethasone (5 mg/kg of body weight on
day 0, intraperitoneally)/rituximab (50 mg/kg administered on
day 0, intraperitoneally), combination of rituximab/dexameth-
asone and GCV (100 mg/kg for 5 days, intraperitoneally), or
GCV only. The tumors were measured regularly, and the tu-
mor volume was calculated as 1/2  a b2, where a represents
the longest axis of tumors in millimeters and b represents the
axis perpendicular to a in millimeters. The tumor-bearing nude
mice were treated with no drug or dexamethasone/rituximab.
Three days later, mice were euthanized, and tumor extracts
were analyzed by immunoblot assay (Fig. 2D). Dexametha-
sone/rituximab led to induction of the lytic EBV protein
(BZLF1 product) in the nude mouse tumors. We next tested
whether GCV can enhance the cytotoxic effect of dexametha-
sone/rituximab in the tumor-bearing nude mice (Fig. 2E).
Treatment with GCV alone did not influence tumor growth.
Treatment with dexamethasone/rituximab suppressed tumor
growth, but the tumors in mice treated with dexamethasone/
rituximab plus GCV were significantly smaller than those in
mice treated with dexamethasone/rituximab alone. Some tu-
mors were not totally obliterated by the dexamethasone/ritux-
imab-plus-GCV treatments. It may be explained that the tu-
mors contained the cells in which the lytic form of EBV
infection had not been fully induced by dexamethasone/ritux-
imab and that therefore the cells could not be susceptible to
GCV cytotoxicity.
One approach to virally targeted therapies for EBV-associ-
ated lymphoproliferative diseases would be to induce lytic
EBV infection intentionally, thereby converting certain antivi-
ral drugs, such as GCV, into cytotoxic forms that kill the host
tumor cells without completion of the viral replicative cycle
and release of infectious EBV particles (5, 10, 25). Although
several chemicals, such as phorbol esters, calcium ionophores,
and sodium butyrate, induce lytic EBV infection (12), whether
these chemicals can be safely used in patients remains un-
known. The initial results of a phase I/II trial, in which patients
were given the combination of arginine butyrate and GCV,
showed that complete clinical responses were achieved in 5 of
10 patients with EBV-associated lymphoproliferative diseases
previously resistant to conventional chemotherapy (4, 14), sug-
gesting that such virally targeted strategies may be promising.
We looked for reagents that can induce the lytic EBV infection
and yet can be safely used in patients. Dexamethasone was
previously shown to activate the lytic EBV genes (19). Here we
demonstrated that the addition of rituximab to dexamethasone
enhanced the efficacy of dexamethasone. Several studies have
shown that rituximab can initiate signal transduction events
that activate protein tyrosine kinases and increase intracellular
Ca2 (8, 20, 21). Since these signal pathways are necessary for
the efficient induction of the viral lytic form following ligation
of B-cell receptors (2, 3, 11), activation of such protein kinases
as well as Ca2 elevation initiated by rituximab are likely to
account for enhancement of the effect of dexamethasone on
inducing the lytic EBV infection.
In the present study we demonstrated that combination
treatment with dexamethasone/rituximab plus GCV was more
effective than dexamethasone/rituximab alone in killing B-lym-
phoma Akata cells with type 1 EBV latency in vitro and in
nude mice. Importantly, such a GCV cytotoxic effect was EBV
dependent. These data suggest that GCV in combination with
dexamethasone/rituximab could be a virally targeted therapy
for EBV-associated B-cell lymphoma. Since both rituximab
and glucocorticoids have been included in treatment regimens
for patients with B-cell lymphoma, our results may have clin-
ical relevance. Recently, Feng et al. (6) reported that doxoru-
bicin can induce lytic EBV infection in EBV-transformed B
cells. Ghetie et al. (7) demonstrated that rituximab can poten-
tiate the cytotoxic effects of doxorubicin in B-lymphoma cells.
Given these observations, the strategy with rituximab plus
dexamethasone/doxorubicin in combination with GCV could
be a stronger virally targeted therapy for EBV-associated B-
cell lymphoma. Clinical studies, therefore, are required to de-
termine whether such strategies can be effective in patients.
Our interest now points toward detailed analysis concerning
whether EBV-positive lymphoma cells containing other types
of EBV latency, such as type 3, also show a favorable response
to combination therapy with ganciclovir and dexamethasone/
rituximab.
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